Bacterial Pulmonary Infection in PICU

Bacterial Infection Clinical Trial

Official title:

Derivation of a Clinical Prediction Rule for Bacterial Pulmonary Infection in Mechanically Ventilated Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00271531
• Other study ID #: 04-072
• Secondary ID: BAMSG 4-03
• Status: Completed
• Phase: N/A
• First received: December 29, 2005
• Last updated: August 11, 2011
• Start date: April 2006
• Est. completion date: May 2008

Study information

• Verified date: October 2009
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to develop a scoring system to allow doctors to accurately identify children on a mechanical ventilator who have bacterial pneumonia. Currently this diagnosis is very difficult to make, resulting in the overuse of antibiotics and the promotion of antibiotic-resistant bacteria in the pediatric intensive care unit (ICU). Four ICUs at 3 children's hospitals will participate. Study participants will include 150 children, ages 2 months to 17 years old who require mechanical ventilation, and in whom the bedside health care providers suspect bacterial pneumonia. Bacteria will be studied by sampling lung fluid through the breathing tube less than 12 hours after starting antibiotics, using a procedure known as "non-bronchoscopic-bronchoalveolar lavage (NB-BAL)." Participants may be involved in study related procedures for up to 31 days.

Description:

The primary objective of this prospective cohort study is to derive a clinical score for predicting the absence of bacterial pulmonary infection in children requiring mechanical ventilation. This study is in preparation for designing an interventional trial whose aim will be to reduce antibiotic use in the pediatric intensive care unit (ICU) and thereby reduce the incidence of acquisition of antibiotic resistant bacteria. Secondary study objectives are to: define key characteristics of bacterial pulmonary infection in children requiring mechanical ventilation: demographics, microbiology, and predisposing factors; and assess the duration and number of antibiotics used for the treatment of pneumonia in this study population and to further assess the amount of antimicrobial therapy that could potentially be avoided in patients with a low probability of bacterial pneumonia as determined by the scoring system. The study hypothesis is that a non-invasive clinical scoring system can be devised for bacterial pulmonary infection in children requiring mechanical ventilation, to identify a threshold score below which the probability of bacterial pulmonary infection is sufficiently low that the clinician can safely withhold or stop antibiotics. The primary outcome (bacterial pneumonia) will be defined as meeting the following 2 criteria: the presence of greater than 10,000 organisms/mL of one or more pathogenic bacterial species obtained by blind non-bronchoscopic bronchoalveolar lavage (NB-BAL) on Day 0 or the isolation of a pathogenic organism from pleural fluid culture obtained between Day -1 through Day 3, in a patient with a pulmonary infiltrate; and persistence of Day 0 pulmonary infiltrate on Day 3 based on a comparison of results of chest x-rays from Days 0 and 3. The secondary endpoint is the duration and number of antibiotics used, for the treatment of pneumonia in the study population and separately in subgroups defined by the threshold score for bacterial pneumonia. Potential predictive parameters for bacterial pulmonary infection will be calculated at the initiation of antibiotics and 3 days later. These parameters will include factors in the Clinical Pulmonary Infection Score (CPIS) developed for adult patients. Additional potential predictors of bacterial pulmonary infection that may be relevant in children also will be recorded and added to the model in an attempt to improve its predictive accuracy. Study outcome will be microbiologically defined bacterial infection, using quantitative lower respiratory tract specimens collected by blind NB-BAL at entry and persistence of infiltrate on chest x-ray at Day 3. The study population will include children, age greater than 48 weeks post-conception and less than 18 years, requiring mechanical ventilation in the pediatric ICU, presence of an abnormal chest x-ray, and initiation of antibiotics less than or equal to 12 hours prior to NB-BAL by the assigned health care providers for suspected bacterial pulmonary infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: May 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Months to 17 Years

Eligibility

Inclusion Criteria:

• Parent or legal guardian has signed the informed consent.

• Age greater than 48 weeks post-conception and less than 18 years of age.

• Requiring mechanical ventilation in the intensive care unit (subjects will not be intubated solely for the purpose of this study).

• Presence of an abnormal chest x-ray (CXR) as determined by the primary care team (Note: if the attending radiologist disagrees with the reading of "abnormal CXR," the subject will be followed for safety and replaced for analysis).

• Initiation of antibiotics by the assigned health care providers for suspected bacterial pneumonia (must be less than or equal to 12 hours prior to undergoing non-bronchoscopic bronchoalveolar lavage [NB-BAL]).

Exclusion Criteria:

• Presence of severe hypoxia (PaO2/FIO2 < 120).

• Documented or suspected increased intracranial pressure.

• Hemodynamic instability, defined as one of the following in the 4 hours preceding study entry:

1. Initiation of any inotropic or vasopressor agents at any dose to improve blood pressure or tissue perfusion.

2. Increase in infusion rate of any inotropic or vasopressor agents to improve blood pressure or tissue perfusion.

• Receipt of intravenous (IV) or oral (PO) antibiotics for suspected bacterial pneumonia for greater than or equal to 12 hours prior to non-bronchoscopic bronchoalveolar lavage (NB-BAL).

• Treatment for a previous episode of suspected bacterial pneumonia within three days prior to NB-BAL.

• Coagulopathy:

1. Documented platelet count <50,000 x 10^6/mL at the time of enrollment (Exception: The subject may be enrolled if he/she receives a platelet infusion as a part of routine care that is completed within one hour of NB-BAL initiation),

2. Extra-corporeal circuit, requiring anticoagulation, or

3. Clinically apparent bleeding deemed important by either the PI or attending intensivist.

• Previous enrollment into this study.

• Cardiopulmonary instability during routine suctioning within 6 hours of NB-BAL.

• Oscillatory ventilation.

• Cystic fibrosis.

• Single ventricle physiology.

• Positive pleural fluid culture results prior to Day -1 during the current hospitalization.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Bacterial Infection
• Bacterial Infections
• Communicable Diseases
• Infection

Locations

Country	Name	City	State
United States	University Hospitals Case Medical Center	Cleveland	Ohio
United States	Kosair Children's Hospital	Louisville	Kentucky
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Washington University in St. Louis	St. Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bacterial pneumonia defined as: presence of >10^4 organisms/mL of one or more pathogenic bacterial species or isolation of a pathogenic organism from pleural fluid culture in a patient with a pulmonary infiltrate; persistence of pulmonary infiltrate.		Day -1 through Day 3.	No
Secondary	Amount of antibiotics, in terms of number and duration, for the treatment of pneumonia used in the study population and separately in subgroups defined by the threshold score for bacterial pneumonia.		Duration of study.	No